Related Experiment Video
Updated: Oct 17, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Similarities and Differences Between HFmrEF and HFpEF
Peixin Li1,2,3, Hengli Zhao1,2,3,4, Jianyu Zhang5
1State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Insights
New heart failure (HF) guidelines define HF with mid-range EF (HFmrEF) as distinct. Research suggests HFmrEF patients may benefit from reduced EF (HFrEF) treatments, though HFmrEF and HF with preserved EF (HFpEF) share some characteristics.
Area of Science:
- Cardiology
- Heart Failure Research
- Clinical Phenotyping
Background:
- Current heart failure (HF) classification includes HF with reduced EF (HFrEF), HF with mid-range EF (HFmrEF), and HF with preserved EF (HFpEF).
- HFmrEF, defined by left ventricular ejection fraction (EF) of 40-49%, is recognized as a unique phenotype, prompting further investigation.
- HFmrEF patients exhibit characteristics intermediate between HFrEF and HFpEF, with similarities in etiology to HFrEF and prognosis to HFpEF.
Purpose of the Study:
- To review current understanding of HFmrEF and HFpEF, focusing on their epidemiology, etiology, clinical indicators, and pathophysiology.
- To explore potential treatment strategies for HFmrEF, particularly the efficacy of HFrEF-focused therapies.
- To discuss the heterogeneity within HFmrEF and HFpEF and its impact on disease prognosis and management.
Main Methods:
- Review of current clinical practice data.
- Analysis of mechanistic studies.
- Examination of observational studies and post-hoc analyses of randomized controlled trials.
Main Results:
- HFmrEF patients share etiological factors with HFrEF but have a prognosis and quality of life closer to HFpEF.
- Growing evidence suggests HFmrEF and HFpEF exhibit significant heterogeneity in presentation and pathophysiology.
- Preliminary data indicate potential benefits of HFrEF treatment strategies (e.g., beta-blockers, ACE inhibitors, ARBs, MRAs, sacubitril/valsartan) for HFmrEF patients.
Conclusions:
- HFmrEF represents a distinct clinical entity requiring further research into its specific mechanisms and optimal treatment.
- Understanding the heterogeneity of HFmrEF and HFpEF is crucial for tailoring effective therapeutic approaches.
- HFrEF treatment paradigms may offer a beneficial therapeutic avenue for patients with HFmrEF, warranting further investigation.
Abstract:
The new guidelines classify heart failure (HF) into three subgroups based on the ejection fraction (EF): HF with reduced EF (HFrEF), HF with mid-range EF (HFmrEF), and HF with preserved EF (HFpEF). The new guidelines regarding the declaration of HFmrEF as a unique phenotype have achieved the goal of stimulating research on the basic characteristics, pathophysiology, and treatment of HF patients with a left ventricular EF of 40-49%. Patients with HFmrEF have more often been described as an intermediate population between HFrEF and HFpEF patients; however, with regard to etiology and clinical indicators, they are more similar to the HFrEF population. Concerning clinical prognosis, they are closer to HFpEF because both populations have a good prognosis and quality of life. Meanwhile, growing evidence indicates that HFmrEF and HFpEF show heterogeneity in presentation and pathophysiology, and the emergence of this heterogeneity often plays a crucial role in the prognosis and treatment of the disease. To date, the exact mechanisms and effective treatment strategies of HFmrEF and HFpEF are still poorly understood, but some of the current evidence, from observational studies and post-hoc analyses of randomized controlled trials, have shown that patients with HFmrEF may benefit more from HFrEF treatment strategies, such as beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and sacubitril/valsartan. This review summarizes available data from current clinical practice and mechanistic studies in terms of epidemiology, etiology, clinical indicators, mechanisms, and treatments to discuss the potential association between HFmrEF and HFpEF patients.
Related Concept Videos
¹H NMR Chemical Shift Equivalence: Homotopic and Heterotopic Protons
Fischer Projections
IR Frequency Region: Fingerprint Region
2D NMR: Heteronuclear Single-Quantum Correlation Spectroscopy (HSQC)
High-Resolution Mass Spectrometry (HRMS)
2D NMR: Overview of Heteronuclear Correlation Techniques
![Protein Film Infrared Electrochemistry Demonstrated for Study of H2 Oxidation by a [NiFe] Hydrogenase](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F55858.jpg&w=3840&q=50)
